티움바이오

321550KOSDAQ

43.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 7.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Tium Bio is a biopharmaceutical company founded by a team that successfully developed and licensed the FDA-approved hemophilia treatment Afstyla, focusing on R&D for rare and intractable diseases. The company develops both small-molecule synthetic drugs and biopharmaceuticals, with several drug candidates in clinical trials, including NCE401 and NBP604. In 2024, Tium Bio acquired Petraon Care Lab, a natural cosmetics OEM/ODM firm, and operates Protiom Science, a CDAO company providing specialized biopharmaceutical process development services.

Number of Employees

67people

Average Salary

57.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

3.35Industry Average 1.200.0Point

2.8x industry avg (risky)

ROE

-42.45Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

39.36Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲59.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲23.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -36.7% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 4,215Won52-week high 13,14052-week low 3,680

1-month return1.0Point

1m -7.06% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral[기재정정]주식매수선택권부여에관한신고2026-09-30
Neutral[기재정정]주식매수선택권부여에관한신고2026-09-30
Neutral[기재정정]주식매수선택권부여에관한신고2026-09-30
Neutral주식매수선택권부여에관한신고2026-09-30
Neutral[기재정정]주식매수선택권부여에관한신고2026-09-30